中国合理用药探索2025，Vol.22Issue(2)：68-72,5.DOI:10.3969/j.issn.2096-3327.2025.02.012
复合布托啡诺时环泊酚用于乳腺旋切术的半数有效剂量
Median Effective Dose of Cipepofol Combined with Butorphanol in Minimally Invasive Breast Gyrotomy
摘要
Abstract
Objective:To determine the median effective dose(ED50)of cipepofol combined with butorphanol in minimally invasive breast gyrotomy under monitored anesthesia care.Methods:A total of 27 patients undergoing elective minimally invasive breast gyrotomy in a hospital from December 1,2023 to February 28,2024 were selected as the study subjects.Butorphanol tartrate injection(20 μg/kg)was administered intravenously at the onset of anesthesia,and cipepofol injection was injected 3 minutes later.The surgery was started once bispectral index(BIS)was≤50 or the modified observer's assessment of alertness/sedation scale(MOAA/S)scale was≤1.The study was conducted according to the modified Dixon sequential method,with the initial dose of cipepofol injection set at 0.4 mg/kg for the first patient.If the patient showed a MOAA/S score of≥4 during skin incision or within 3 minutes,or showed reactions such as frowning or body movement that affected the surgical procedure,it was considered a positive response.In this case,the dose for the next patient would be increased by 0.04 mg/kg.Otherwise,the dose would be decreased by 0.04 mg/kg.The study would be terminated when seven crossover points between positive and negative responses were observed.Results:The ED50 of cipepofol combined with butorphanol in minimally invasive breast gyrotomy was 0.452 mg/kg(95%CI 0.421～0.486 mg/kg)and the ED95 was 0.520 mg/kg(95%CI 0.486～0.714 mg/kg).Conclusion:The ED50 of cipepofol combined with butorphanol in minimally invasive breast gyrotomy under monitored anesthesia care was 0.452 mg/kg(95%CI 0.421～0.486 mg/kg).关键词
环泊酚/布托啡诺/乳腺旋切术/监护麻醉/半数有效剂量Key words
cipepofol/butorphanol/minimally invasive breast gyrotomy/monitored anesthesia care/median effective dose分类
医药卫生引用本文复制引用
张怡,李娅茹,李芳坤,李一,朱建坡..复合布托啡诺时环泊酚用于乳腺旋切术的半数有效剂量[J].中国合理用药探索,2025,22(2):68-72,5.基金项目
河南省中医药科学研究专项课题(2022JDZX033) （2022JDZX033）
